NABH-accredited 2,000-bed multi-speciality hospital chain based in Coimbatore, Tamil Nadu.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 420 | 499 | 598 | 708 | 878 | 1.1k | 1.2k | 1.3k |
| Borrowings | 543 | 623 | 550 | 511 | 310 | 415 | 399 | 403 |
| Other Liabilities | 134 | 148 | 184 | 209 | 240 | 299 | 328 | 344 |
| Total Liabilities | 1.1k | 1.3k | 1.3k | 1.4k | 1.4k | 1.8k | 1.9k | 2.1k |
| AssetsFixed Assets | 643 | 1.0k | 1.1k | 1.1k | 1.1k | 1.3k | 1.3k | 1.5k |
| CWIP | 300 | 45 | 5 | 23 | 39 | 154 | 224 | 135 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other Assets | 165 | 203 | 253 | 328 | 282 | 364 | 406 | 457 |
| Total Assets | 1.1k | 1.3k | 1.3k | 1.4k | 1.4k | 1.8k | 1.9k | 2.1k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 126 | 166 | 186 | 262 | 263 | 344 | 353 | 362 |
| Cash from Investing | -352 | -349 | -180 | -292 | -358 | -290 | -612 | -230 |
| Cash from Financing | 160 | 113 | 38 | -119 | -86 | -243 | 62 | -58 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -151 | -102 | 5 | 163 | 136 | 206 | 1 | 111 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (14.0×) and current (26.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 28.1% growth and a 14× exit, ₹5986 only delivers your return if you pay ₹5,032. The price is currently baking in 32% growth.
EPS grows 28.1%/yr for 5 years, then fades to 6% over 2, exits at 14×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 28.1% | 286.18 |
| FY28 | 28.1% | 366.59 |
| FY29 | 28.1% | 469.60 |
| FY30 | 28.1% | 601.56 |
| FY31 | 28.1% | 770.60 |
| FY32 | 17.1% ·fade | 901.99 |
| FY33 | 6.0% ·fade | 956.11 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.